Novavax Stock Moves Higher Wednesday: What's Driving the Action?

Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID?

Moderna reported positive Phase III results for its personalized mRNA cancer therapy (intismeran autogene) developed with Merck, showing significant improvements in recurrence-free and distant metastasis-free survival in melanoma patients. The breakthrough validates Moderna's mRNA platform beyond vaccines and opens opportunities across multiple tumor types, while the company simultaneously expands its respiratory vaccine portfolio with RSV, flu, and combination vaccines to reduce COVID-19 dependence.

Novavax (NVAX) Laps the Stock Market: Here's Why

Novavax (NVAX) closed at $9.42, up 1.29%, outperforming the S&P 500's 0.86% gain. The stock has appreciated 14.25% over the past month. However, the company faces headwinds with projected quarterly EPS of -$0.22 and revenue expected to decline 39.01% year-over-year. Annual projections show -$0.47 EPS and 68.15% revenue decline. Novavax holds a Zacks Rank of #3 (Hold), with consensus EPS projections down 10.12% in the past 30 days.

Novavax Stock Rises Despite No Confirmed News Behind the Matrix-M Rumor

Novavax is rising on investors reaction to an unconfirmed rumor that Matrix-M has a favorable safety profile with self-limiting side effects.

Novavax shares are trading higher. Strength may be due to an increase in investor attention related to an unconfirmed rumor suggesting that Matrix-M has a favorable safety profile with mostly mild-to-moderate, self-limiting side effects.

Healthcare ETFs Were Left Behind. JPMorgan Sees the Money Coming Back

JPMorgan sees healthcare ETF flows reversing, with Eli Lilly and AbbVie among stocks that could benefit from renewed sector rotation.

PVG Sends Open Letter to Anavex Stockholders Detailing the Need for Change at the Company

PVG Asset Management, a significant shareholder of Anavex Life Sciences, has launched a proxy contest calling for complete board reconstitution, citing operational failures, governance issues, and failure to deliver shareholder value. PVG has nominated six biotechnology-experienced directors to replace the current board, criticizing the company's underperformance relative to peers, delayed clinical trials for its lead drug blarcamesine, significant executive departures, and recent stock decline amid broader biotech sector gains.